肿瘤研究与临床
腫瘤研究與臨床
종류연구여림상
CANCER RESEARCH AND CLINIC
2009年
6期
403-405
,共3页
癌,非小细胞肺%同步放化疗%治疗效果
癌,非小細胞肺%同步放化療%治療效果
암,비소세포폐%동보방화료%치료효과
Carcinoma,non-small-cell lung%Concurrent chemoradiotherapy%Treatment outcome
目的 比较两种同步放化疗方案对不能手术的Ⅲ期非小细胞肺癌(NSCLC)的疗效及不良反应.方法 52例不能手术的Ⅲ期NSCLC患者,随机分成两组,A组每周紫杉醇方案,B组三周紫杉醇+顺铂(DDP)方案.两组的放疗方法相同,均采用常规分割放疗,每次2.0Gy,每周5次.原发肿瘤灶总剂量60~64 Gy.A组在放疗同时给予紫杉醇每周45 mg/m2;B组给予紫杉醇135 mg/m2第1、22天+DDP 30 mg/m2第2天至第4天,第23天至第25天.结果 两组的有效率(CR+PR)分别为78%和74%(P>0.05),而两组CR率分别为22%和14%(P<0.05).两组1、2、3、5年局部控制率分别为78%、57%、32%、8%和59%、26%、18%、5%,差异有统计学意义(P=0.0493);1、2、3和5年生存率分别为82%、62%、37%、12%和64%、43%、18%和9%,差异接近具有统计学意义(P=0.0532).两组重度不良反应差异无统计学意义(P>0.05).结论 每周小剂量同步放化疗方案可提高NSCLC的局部控制率,并有望延长患者生存时间.
目的 比較兩種同步放化療方案對不能手術的Ⅲ期非小細胞肺癌(NSCLC)的療效及不良反應.方法 52例不能手術的Ⅲ期NSCLC患者,隨機分成兩組,A組每週紫杉醇方案,B組三週紫杉醇+順鉑(DDP)方案.兩組的放療方法相同,均採用常規分割放療,每次2.0Gy,每週5次.原髮腫瘤竈總劑量60~64 Gy.A組在放療同時給予紫杉醇每週45 mg/m2;B組給予紫杉醇135 mg/m2第1、22天+DDP 30 mg/m2第2天至第4天,第23天至第25天.結果 兩組的有效率(CR+PR)分彆為78%和74%(P>0.05),而兩組CR率分彆為22%和14%(P<0.05).兩組1、2、3、5年跼部控製率分彆為78%、57%、32%、8%和59%、26%、18%、5%,差異有統計學意義(P=0.0493);1、2、3和5年生存率分彆為82%、62%、37%、12%和64%、43%、18%和9%,差異接近具有統計學意義(P=0.0532).兩組重度不良反應差異無統計學意義(P>0.05).結論 每週小劑量同步放化療方案可提高NSCLC的跼部控製率,併有望延長患者生存時間.
목적 비교량충동보방화료방안대불능수술적Ⅲ기비소세포폐암(NSCLC)적료효급불량반응.방법 52례불능수술적Ⅲ기NSCLC환자,수궤분성량조,A조매주자삼순방안,B조삼주자삼순+순박(DDP)방안.량조적방료방법상동,균채용상규분할방료,매차2.0Gy,매주5차.원발종류조총제량60~64 Gy.A조재방료동시급여자삼순매주45 mg/m2;B조급여자삼순135 mg/m2제1、22천+DDP 30 mg/m2제2천지제4천,제23천지제25천.결과 량조적유효솔(CR+PR)분별위78%화74%(P>0.05),이량조CR솔분별위22%화14%(P<0.05).량조1、2、3、5년국부공제솔분별위78%、57%、32%、8%화59%、26%、18%、5%,차이유통계학의의(P=0.0493);1、2、3화5년생존솔분별위82%、62%、37%、12%화64%、43%、18%화9%,차이접근구유통계학의의(P=0.0532).량조중도불량반응차이무통계학의의(P>0.05).결론 매주소제량동보방화료방안가제고NSCLC적국부공제솔,병유망연장환자생존시간.
Objective To evaluate the efficacy and toxicity of concurrent chemoradiotherapy for unresectable stage Ⅲ non-small-cell lung cancer. Methods Fifty-two patients with unresectable stage Ⅲ non-small-cell lung cancer were randomized into group A and B. The method of radiotherapy was the same. All patients were irradiated 2.0 Gy/per fraction, five fractions a week, the total radiation dose was 60~ 64 Gy in tumor. Group A received chemotherapy with 45 mg/m2 of paclitaxel on every Monday. Group B received 30 mg/m2 of cisplatin on days 2 to 4 and 23 to 25 and 135 mg/m2 of paclitaxel on days 1 and 22 concomitant with the radiotherapy. Results The CR (complete response) rates were 22 % and 14 % respectively(P<0.05). Local tumor control time of group A was longer than group B(P=0.0493). Survival rate of group A was higher than group B (P=0.0532). The difference between the toxicity was not statistically significant in both groups (P>0.05). Conclusion The efficacy of low-dose every week was more effective than high-dose every three weeks and it's local tumor control time and survival was longer than later.